- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01023074
Effects of Training on Central Auditory Function in Multiple Sclerosis
September 10, 2018 updated by: VA Office of Research and Development
The purpose of this study is to characterize the central auditory processing (CAP) deficits that result from multiple sclerosis (MS).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Five general types of evaluations will be employed over multiple study sessions at the National Center for Rehabilitative Auditory Research (NCRAR).
First, a neurologist will review the subject's medical history and perform a neurologic exam to confirm MS diagnosis.
Second, peripheral auditory function will be evaluated using a standard set of routine audiometric tests.
Additionally, subjects will complete a case history and series of hearing handicap inventories.
Third, a battery of behavioral procedures will be used to characterize central auditory processing.
Fourth, auditory evoked potential studies will be performed.
Emphasis here will be upon evoked potentials whose putative neural generators lie within the central auditory nervous system.
Fifth, subjects will receive magnetic resonance imaging (MRI) evaluation to determine sites and amount of neural degeneration.
Study Type
Interventional
Enrollment (Actual)
52
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239
- VA Portland Health Care System, Portland, OR
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- age 21-65 years;
- a clinical or laboratory supported diagnosis of "definite" MS;
- a diagnosis of relapsing-remitting, primary progressive, or secondary progressive MS;
- a Kurtzke Expanded Disability Status Score (EDSS) of 0 to 7.0, inclusive;
- no history of a clinical relapse or change in EDSS for three months preceding entry into the study; and
- a brain MRI scan that shows at least three white-matter lesions on T2-weighted images consistent with MS
Exclusion Criteria:
- current major disease or disorder other than MS (e.g., cancer, end-stage renal disease, end-stage cardiopulmonary disease, post-traumatic stress disorder, diabetes);
- other neurological conditions that could interfere with the ability to respond to tests and questionnaires;
- non-native speaker of English (since test materials are presented in English);
- pregnant (due to potential negative effects on the fetus during fMRI);
- more than a mild degree (less than a 40 dB HL four-frequency pure-tone average [PTA]) of hearing loss bilaterally (since the presence of more than a mild degree of peripheral hearing impairment may impact CAP test results);
- metal implants (due to fMRI constraints); and
- left-handedness
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
NO_INTERVENTION: Non-MS Control
Non-MS control group
|
|
ACTIVE_COMPARATOR: MS: Auditory Training
MS group receiving auditory training
|
the study was originally set up so that half of the MS subjects would received auditory training.
This intervention has since been discontinued.
|
PLACEBO_COMPARATOR: MS: Control Activity
MS group not receiving auditory training, doing control activity
|
MS group not receiving auditory training, doing control activity
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Electrophysiological Auditory Test
Time Frame: Recordings were conducted during one session
|
auditory P300 amplitude in response to "rare" 1000 Hz tones
|
Recordings were conducted during one session
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Neural Magnetic Resonance Imaging (MRI)
Time Frame: Results were recorded during one scanning session
|
Gray matter volume
|
Results were recorded during one scanning session
|
SCAN-A: Competing Words Test
Time Frame: Test administered during one session
|
The SCAN-A: Competing Words Test assesses participants' auditory processing abilities via a dichotic listening task.
Lists of word pairs are presented separately to each ear, and participants repeat the words they hear.
Possible range of scores = 0-20, with higher scores indicating better performance.
|
Test administered during one session
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Dennis N. Bourdette, MD, VA Portland Health Care System, Portland, OR
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2007
Primary Completion (ACTUAL)
June 1, 2011
Study Completion (ACTUAL)
June 1, 2011
Study Registration Dates
First Submitted
November 30, 2009
First Submitted That Met QC Criteria
December 1, 2009
First Posted (ESTIMATE)
December 2, 2009
Study Record Updates
Last Update Posted (ACTUAL)
October 9, 2018
Last Update Submitted That Met QC Criteria
September 10, 2018
Last Verified
September 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- B4762-R
- NCRAR-VA-04-1205 (OTHER: Portland VA Medical Center IRB)
- OHSU - 3188 (OTHER: Oregon Health Sciences University IRB)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Auditory training
-
Hong Kong Baptist UniversityThe Hong Kong Polytechnic University; Education University of Hong KongCompletedAutism Spectrum DisorderHong Kong
-
Nottingham University Hospitals NHS TrustCompleted
-
Gallaudet UniversityDepartment of Health and Human ServicesRecruitingHearing Loss | DeafnessUnited States
-
University of Maryland, College ParkNational Institute on Aging (NIA)Recruiting
-
VA Office of Research and DevelopmentNorthwestern University Feinberg School of Medicine; Shirley Ryan AbilityLab; Northwestern Memorial HospitalCompletedTraumatic Brain Injury | Coma | Minimally Conscious State | Vegetative StateUnited States
-
University of Maryland, College ParkNational Institutes of Health (NIH); National Institute on Aging (NIA)RecruitingAuditory Perceptual Disorders | Aging ProblemsUnited States
-
Education University of Hong KongNot yet recruiting
-
East Carolina UniversityWithdrawn
-
VA Greater Los Angeles Healthcare SystemCompletedSchizophreniaUnited States
-
National Taiwan University HospitalCompletedParkinson's DiseaseTaiwan